ValuEngine lowered shares of Tetraphase Pharmaceuticals (NASDAQ:TTPH) from a sell rating to a strong sell rating in a research note published on Friday.

Several other research analysts have also weighed in on the company. Stifel Nicolaus reiterated a buy rating and issued a $13.00 price objective on shares of Tetraphase Pharmaceuticals in a research report on Tuesday, September 12th. Piper Jaffray Companies started coverage on Tetraphase Pharmaceuticals in a research report on Monday, August 28th. They issued an overweight rating and a $14.00 price objective for the company. Zacks Investment Research upgraded Tetraphase Pharmaceuticals from a sell rating to a hold rating in a research report on Saturday, October 28th. BMO Capital Markets increased their price objective on Tetraphase Pharmaceuticals from $13.00 to $24.00 and gave the stock an outperform rating in a research report on Wednesday, October 4th. Finally, Needham & Company LLC reiterated a hold rating on shares of Tetraphase Pharmaceuticals in a research report on Sunday, September 17th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the stock. Tetraphase Pharmaceuticals presently has an average rating of Hold and a consensus target price of $15.15.

Tetraphase Pharmaceuticals (TTPH) opened at $6.00 on Friday. Tetraphase Pharmaceuticals has a 52-week low of $3.57 and a 52-week high of $9.93.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last issued its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($0.63) earnings per share for the quarter, hitting the consensus estimate of ($0.63). The company had revenue of $4.10 million during the quarter, compared to analyst estimates of $1.59 million. Tetraphase Pharmaceuticals had a negative return on equity of 88.27% and a negative net margin of 1,382.33%. The firm’s revenue for the quarter was up 355.6% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.58) earnings per share. analysts predict that Tetraphase Pharmaceuticals will post -2.88 EPS for the current fiscal year.

In other news, Director L Patrick Gage purchased 3,880 shares of the stock in a transaction dated Wednesday, November 29th. The stock was acquired at an average cost of $6.45 per share, for a total transaction of $25,026.00. Following the completion of the transaction, the director now directly owns 38,880 shares in the company, valued at approximately $250,776. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Jacques Dumas sold 8,750 shares of the firm’s stock in a transaction on Tuesday, October 31st. The stock was sold at an average price of $6.03, for a total value of $52,762.50. Following the transaction, the insider now owns 8,750 shares of the company’s stock, valued at $52,762.50. The disclosure for this sale can be found here. Company insiders own 5.50% of the company’s stock.

Several institutional investors and hedge funds have recently added to or reduced their stakes in TTPH. JPMorgan Chase & Co. purchased a new position in shares of Tetraphase Pharmaceuticals during the third quarter worth $7,915,000. Canada Pension Plan Investment Board raised its stake in shares of Tetraphase Pharmaceuticals by 54.4% in the third quarter. Canada Pension Plan Investment Board now owns 2,554,100 shares of the biopharmaceutical company’s stock valued at $17,470,000 after acquiring an additional 900,000 shares in the last quarter. Numeric Investors LLC raised its stake in shares of Tetraphase Pharmaceuticals by 1,363.3% in the second quarter. Numeric Investors LLC now owns 754,364 shares of the biopharmaceutical company’s stock valued at $5,379,000 after acquiring an additional 702,812 shares in the last quarter. EcoR1 Capital LLC acquired a new stake in shares of Tetraphase Pharmaceuticals in the second quarter valued at $4,516,000. Finally, Dimensional Fund Advisors LP raised its stake in shares of Tetraphase Pharmaceuticals by 73.6% in the second quarter. Dimensional Fund Advisors LP now owns 1,101,255 shares of the biopharmaceutical company’s stock valued at $7,853,000 after acquiring an additional 466,955 shares in the last quarter. Institutional investors and hedge funds own 58.19% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Tetraphase Pharmaceuticals (TTPH) Cut to Strong Sell at ValuEngine” was originally published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this story on another website, it was illegally copied and republished in violation of United States and international copyright laws. The correct version of this story can be viewed at https://theolympiareport.com/2017/12/05/tetraphase-pharmaceuticals-ttph-cut-to-strong-sell-at-valuengine.html.

About Tetraphase Pharmaceuticals

Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Ratings for Tetraphase Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.